Cargando…

Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic

BACKGROUND: The reward deficiency syndrome hypothesis posits that genes are responsible for reward dependence and related behaviors. There is evidence that both bulimia and anorexia nervosa, especially in women, have been linked to a lifetime history of substance use disorder (SUD). There are diffic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beitscher-Campbell, Harriet, Blum, Kenneth, Febo, Marcelo, Madigan, Margaret A., Giordano, John, Badgaiyan, Rajendra D., Braverman, Eric R., Dushaj, Kristina, Li, Mona, Gold, Mark S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Akadémiai Kiadó 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264422/ https://www.ncbi.nlm.nih.gov/pubmed/27502054 http://dx.doi.org/10.1556/2006.5.2016.055

Ejemplares similares

KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?
por: McLaughlin, Thomas, et al.
Publicado: (2016)

Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term
por: Blum, Kenneth, et al.
Publicado: (2016)

Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2017)

Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape
por: Blum, Kenneth, et al.
Publicado: (2017)

Hypothesizing that a Pro-Dopaminergic Regulator (KB220z(™) Liquid Variant) can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence
por: Blum, Kenneth, et al.
Publicado: (2016)

Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality
por: Blum, Kenneth, et al.
Publicado: (2015)

NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity
por: Schoenthaler, Stephen J., et al.
Publicado: (2015)

Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake
por: Duquette, Lucien L, et al.
Publicado: (2016)

Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant) in Cognitively Impaired Patients
por: Braverman, Eric R., et al.
Publicado: (2015)

Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction
por: Blum, Kenneth, et al.
Publicado: (2015)

Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?
por: McLaughlin, Thomas, et al.
Publicado: (2017)

Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms
por: Blum, Kenneth, et al.
Publicado: (2015)

Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward
por: Blum, Kenneth, et al.
Publicado: (2015)

“Pro-dopamine regulation (KB220Z™)” as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America
por: Blum, K, et al.
Publicado: (2016)

Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction
por: Blum, Kenneth, et al.
Publicado: (2015)

Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
por: Madigan, Margaret A., et al.
Publicado: (2022)

Menopause Analytical Hormonal Correlate Outcome Study (MAHCOS) and the Association to Brain Electrophysiology (P300) in a Clinical Setting
por: Braverman, Eric R., et al.
Publicado: (2014)

Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z
por: Febo, Marcelo, et al.
Publicado: (2017)

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Correction: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Retraction: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain
por: Blum, Kenneth, et al.
Publicado: (2014)

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018)

High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial
por: Moran, Mark, et al.
Publicado: (2021)

Preliminary Hormonal Correlations in Female Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bio-Identical Replacement Therapy (MHRT)
por: Braverman, Eric R, et al.
Publicado: (2013)

Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients
por: Braverman, Eric R., et al.
Publicado: (2013)

Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence
por: Blum, Kenneth, et al.
Publicado: (2013)

Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
por: Blum, Kenneth, et al.
Publicado: (2015)

Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation
por: Blum, Kenneth, et al.
Publicado: (2022)

Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission
por: Blum, Kenneth, et al.
Publicado: (2017)

Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors
por: Gupta, Ashim, et al.
Publicado: (2022)

Neurogenetic and Epigenetic Aspects of Cannabinoids
por: Dennen, Catherine A., et al.
Publicado: (2022)

Calvin klein (CK) designer cocktail, new “Speedball” is the “grimm reaper”: Brain dopaminergic surge a potential death sentence
por: Gold, Mark S, et al.
Publicado: (2020)

Opioid and dopamine genes interact to predict precision naltrexone response in alcohol use disorder: Interpretation misfires
por: Blum, Kenneth, et al.
Publicado: (2021)

Bariatric surgery: Potential post-operative heightened sensitivity to substances or behaviors
por: Thanos, Panayotis K., et al.
Publicado: (2021)

Addiction Research and Therapy in the 21(st) Century: Providing a Forum for Evidence -Based Addiction Medicine
por: Blum, Kenneth, et al.
Publicado: (2013)

How to Combat the Global Opioid Crisis
por: Dennen A., Catherine, et al.
Publicado: (2023)

Proposing FDA consideration for the treatment and prophylaxis of opioid and psychostimulant abuse to incorporate the induction of DNA guided dopamine homeostasis: Anti-reward deficiency restoration solution (ARDS)
por: Blum, Kenneth, et al.
Publicado: (2020)

Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual
por: Blum, Kenneth, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hfh1jkssst5f8du6cndqeudeu6